cat no | io1069
A rapidly maturing, physiologically relevant, functional system for investigating the role of the homozygous PSEN1 M146L mutation in early-onset Alzheimer's disease (AD). This in vitro disease cell model recapitulates an increase in the amyloid beta peptide ratios observed in AD patients.
ioGlutamatergic Neurons PSEN1 M146L/M146L are opti‑ox deterministically programmed glutamatergic neurons carrying a genetically engineered homozygous M146L mutation in the PSEN1 gene encoding presenilin 1 protein.
This disease model is part of an Alzheimer's disease panel of human iPSC-derived cells that can be incorporated into translational research and drug discovery workflows. Two additional clones for the PSEN1 M146L/M146L mutation are available for scientists who wish to repeat their experiments in multiple independent clones, please enquire. All disease models are genetically matched to the wild-type control, ioGlutamatergic Neurons. Additional mutations in the AD panel include heterozygous PSEN1 M146L, heterozygous and homozygous APP KM670/671NL and APP V717I.
Confidently investigate your phenotype of interest across multiple clones with our disease model clone panel. Detailed characterisation data (below) and bulk RNA sequencing data (upon request) help you select specific clones if required.
per vial
A maximum number of 20 vials applies. If you would like to order more than 20 vials, please contact us at orders@bit.bio.
Disease-related phenotype
Increased ratio of A𝛽42:40 and A𝛽42:38 peptides compared to the genetically matched control, measured by immunoassay.
Make True Comparisons
Pair the Alzheimer's disease model cells with the genetically matched wild-type ioGlutamatergic Neurons to investigate the impact of the PSEN1 missense mutation on early-onset AD.
Quick
The disease model cells and wild-type control are experiment ready as early as 2 days post revival, and form structural neuronal networks at 11 days.
PSEN1 M146L disease models recapitulate an increase in amyloid beta peptide ratios observed in Alzheimer's disease patients
ioGlutamatergic Neurons PSEN1 M146L/M146L express neuron-specific markers comparably to the wild type control
ioGlutamatergic Neurons PSEN1 M146L/M146L form structural neuronal networks by day 11
ioGlutamatergic Neurons PSEN1 M146L/M146L demonstrate gene expression of neuronal-specific and glutamatergic-specific markers following deterministic programming
Disease-related PSEN1 is expressed in ioGlutamatergic Neurons PSEN1 M146L/M146L following deterministic programming
bit.bio
V11
bit.bio
2024
Professor Deepak Srivastava
Professor of Molecular Neuroscience and Group Leader, MRC Centre for Developmental Disorders
King’s College London
Emmanouil Metzakopian | Vice President, Research and Development | bit.bio
Javier Conde-Vancells | Director Product Management | bit.bio
Chakraborty et al
Nature Communications
2023
Featuring ioGlutamatergic Neurons
Dr Ania Wilczynska | Head of Computational Genomics | Non-Clinical | bit.bio
Innovation showcase talk at ISSCR
Marius Wernig MD, PhD | Stanford
Mark Kotter, MD, PhD | bit.bio
Oosterveen, et al
bit.bio & Charles River Laboratories
2023
Qiaojin Lin et al
The EMBO Journal
2023
Featuring opti-ox powered hiPSC-derived glutamatergic neurons with constitutive expression of Cas9
Mark Kotter | CEO and founder | bit.bio
Marius Wernig | Professor Departments of Pathology and Chemical and Systems Biology | Stanford University
Madeleine Garrett | Field Application Specialist | bit.bio
Read this blog on glutamatergic neuron cell culture for our top tips on careful handling, cell plating and media changes to achieve success from the outset.
Further your disease research by pairing our wild type cells with isogenic disease models.